MTHFR Gene Test in Australia

What an MTHFR test is

MTHFR testing reads the DNA sequence at two well-studied positions in the MTHFR gene and reports which version of the gene you inherited from each parent.

MTHFR stands for methylenetetrahydrofolate reductase, an enzyme that converts one form of folate into 5-methyltetrahydrofolate, the form the body uses to convert homocysteine back into methionine. Two single-letter changes in the gene are common enough to be worth naming: C677T and A1298C.

You carry two copies of every gene. For C677T that means you are either wild type (no copies of the variant), heterozygous (one copy) or homozygous (two copies). Laboratory studies suggest the homozygous C677T genotype produces an enzyme with roughly 30–40% of typical activity at body temperature, and the heterozygous state around 60–70%. The A1298C variant has a smaller measured effect.

The single most important framing point: these are common variants, not a rare disease. Roughly half of people of European ancestry carry at least one copy of C677T, and something on the order of one in ten is homozygous. A finding shared with a tenth of the population is a description of normal human variation, not a diagnosis.

This also means the result cannot change. Unlike homocysteine, B12 or ferritin, your genotype is fixed at conception. There is no benefit to repeating the test, and no diet, supplement or lifestyle change alters the answer.

Why MTHFR is tested — and why it often is not

MTHFR genotyping is occasionally used to help explain a persistently raised homocysteine level, but Australian guidance discourages it as a routine test in healthy people.

The clinically defensible use is narrow: when homocysteine is unexplainedly elevated after nutritional and renal causes have been considered, knowing the genotype can complete the picture. Some metabolic and haematology services also consider it in specific inherited-disease work-ups.

Outside those settings, Australian professional bodies have been consistent and blunt. The RACGP and Choosing Wisely Australia have both cautioned against routine MTHFR genotyping, on the basis that the result rarely changes management. Testing for thrombophilia risk is a particular example — MTHFR genotype is no longer regarded as a useful predictor of venous thromboembolism, and a positive result does not on its own justify anticoagulation, aspirin or altered contraceptive or pregnancy management.

The reason is straightforward. Even in a homozygous carrier, adequate folate intake largely compensates for the reduced enzyme efficiency. What matters functionally is the homocysteine, B12 and folate result — the numbers that describe how the pathway is actually performing today. If those are normal, the genotype has little to add.

• Reasonable: persistently raised homocysteine after other causes have been assessed by a doctor.
• Reasonable: as part of a specialist-directed metabolic or haematology work-up.
• Not supported: routine screening of healthy adults.
• Not supported: as a stand-alone predictor of clotting risk, miscarriage risk or cardiovascular disease.

What a homozygous or heterozygous result means

Carrying one or two copies of C677T means the MTHFR enzyme works somewhat less efficiently — it does not mean you have a disease, and in the presence of adequate folate the practical effect is usually small.

Homozygous C677T carriers have, on average, modestly higher homocysteine levels than non-carriers, and the difference is most pronounced when folate intake is low. In populations with folate-fortified food supplies — Australia has mandated folic acid fortification of bread-making flour since 2009 — the average difference narrows considerably.

Heterozygous carriers show a smaller effect again, and for most people it is not detectable in their blood results at all. Compound states (one copy of C677T plus one copy of A1298C) are sometimes reported and are generally treated as intermediate.

A positive result should not be treated as a reason to start high-dose supplementation on your own. Very high folic acid intake can mask a coexisting B12 deficiency, and the specific 'methylated' supplement forms marketed to MTHFR carriers have not been shown in good-quality trials to outperform ordinary folate in people with adequate status. Any decision about supplementation belongs with your GP, informed by your actual homocysteine, B12 and folate results.

What a wild-type (negative) result means

A wild-type result means you carry no copies of the tested variants, so MTHFR is not contributing to any elevation in your homocysteine.

This is genuinely useful information in one narrow situation: if your homocysteine is raised and your genotype is wild type, the cause lies elsewhere — most often B12 or folate deficiency, kidney function, thyroid status, a medicine, or lifestyle factors such as heavy smoking.

A wild-type result does not mean your methylation pathway is functioning well. MTHFR is one enzyme among many in the cycle, and nutritional deficiency will impair the pathway regardless of genotype. If you want to know whether the pathway is working, measure homocysteine, B12 and folate.

How Australian laboratories report MTHFR results

There is no numeric reference range for a genetic test — Australian laboratories report MTHFR results as a genotype at each tested position, usually alongside a short interpretive comment.

Who should consider testing

MTHFR testing is worth considering when a doctor is investigating an unexplained raised homocysteine, and rarely otherwise.

If your goal is to understand how your folate and B12 metabolism is actually performing, a methylation blood panel measuring homocysteine, B12 and folate answers that question directly, changes with treatment, and can be repeated.

• People with a persistently elevated homocysteine after B12, folate, thyroid and kidney causes have been assessed.
• People undergoing a specialist metabolic or haematology work-up where the genotype has been requested.
• People who want the result for completeness and understand it will most likely not change anything.

How testing works with FORM in Australia

You choose the test, we issue an Australian pathology request form, you walk in for collection at an accredited centre, and you receive your genotype with a written plain-English explanation of what it does and does not mean.

• No referral from your own GP is required. Privately requested pathology is arranged under a request from a registered medical practitioner working with our accredited lab partner.
• Collection is a walk-in at Laverty (Healius) pathology centres in every Australian state and territory.
• No fasting and no preparation — genotype is unaffected by diet, medicines or timing.
• Genetic results carry particular privacy considerations; we recommend discussing them with your GP, especially if you are considering telling family members.
• FORM is a diagnostic blood-testing service. We do not prescribe, supply or manage medicines.
• Australian ordering is currently pre-sale. Join the waitlist for launch notification.